The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

Marc S. Raab, Sheeba K. Thomas, Enrique M. Ocio, Andreas Guenther, Yeow Tee Goh, Moshe Talpaz, Nicolas Hohmann, Sylvia Zhao, Fang Xiang, Carl Simon, K. Gary Vanasse, Shaji K Kumar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PIM447, a novel pan-PIM inhibitor, has shown preclinical activity in multiple myeloma (MM). In the multicenter, open-label, first-in-human study, patients with relapsed and/or refractory MM were enrolled to determine the maximum-tolerated dose (MTD) or recommended dose (RD), safety, pharmacokinetics, and preliminary anti-myeloma activity of PIM447. PIM447 was administered in escalating oral doses of 70–700 mg once daily (q.d.) for 28-day continuous cycles. Seventy-nine patients with a median of four prior therapies were enrolled. Seventy-seven patients (97.5%) had an adverse event (AE) suspected as treatment related, with treatment-related grade 3/4 AEs being mostly hematologic. Eleven dose-limiting toxicities occurred, and an MTD of 500 mg q.d. and an RD of 300 mg q.d. were established. The main reason for discontinuation was disease progression in 54 patients (68.4%). In the entire study population, a disease control rate of 72.2%, a clinical benefit rate of 25.3%, and an overall response rate of 8.9% were observed per modified International Myeloma Working Group criteria. Median progression-free survival at the RD was 10.9 months. PIM447 was well tolerated and demonstrated single-agent antitumor activity in relapsed/refractory MM patients, providing proof of principle for Pim (Proviral Insertions of Moloney Murine leukemia virus) kinase inhibition as a novel therapeutic approach in MM.

Original languageEnglish (US)
JournalLeukemia
DOIs
StatePublished - Jan 1 2019

Fingerprint

Multiple Myeloma
Phosphotransferases
Maximum Tolerated Dose
Moloney murine leukemia virus
Therapeutics
Antineoplastic Agents
Disease-Free Survival
Disease Progression
Pharmacokinetics
Safety
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. / Raab, Marc S.; Thomas, Sheeba K.; Ocio, Enrique M.; Guenther, Andreas; Goh, Yeow Tee; Talpaz, Moshe; Hohmann, Nicolas; Zhao, Sylvia; Xiang, Fang; Simon, Carl; Vanasse, K. Gary; Kumar, Shaji K.

In: Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Raab, MS, Thomas, SK, Ocio, EM, Guenther, A, Goh, YT, Talpaz, M, Hohmann, N, Zhao, S, Xiang, F, Simon, C, Vanasse, KG & Kumar, SK 2019, 'The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma', Leukemia. https://doi.org/10.1038/s41375-019-0482-0
Raab, Marc S. ; Thomas, Sheeba K. ; Ocio, Enrique M. ; Guenther, Andreas ; Goh, Yeow Tee ; Talpaz, Moshe ; Hohmann, Nicolas ; Zhao, Sylvia ; Xiang, Fang ; Simon, Carl ; Vanasse, K. Gary ; Kumar, Shaji K. / The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. In: Leukemia. 2019.
@article{2fa66c7874ed4828ad1523fd3e4d7a06,
title = "The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma",
abstract = "PIM447, a novel pan-PIM inhibitor, has shown preclinical activity in multiple myeloma (MM). In the multicenter, open-label, first-in-human study, patients with relapsed and/or refractory MM were enrolled to determine the maximum-tolerated dose (MTD) or recommended dose (RD), safety, pharmacokinetics, and preliminary anti-myeloma activity of PIM447. PIM447 was administered in escalating oral doses of 70–700 mg once daily (q.d.) for 28-day continuous cycles. Seventy-nine patients with a median of four prior therapies were enrolled. Seventy-seven patients (97.5{\%}) had an adverse event (AE) suspected as treatment related, with treatment-related grade 3/4 AEs being mostly hematologic. Eleven dose-limiting toxicities occurred, and an MTD of 500 mg q.d. and an RD of 300 mg q.d. were established. The main reason for discontinuation was disease progression in 54 patients (68.4{\%}). In the entire study population, a disease control rate of 72.2{\%}, a clinical benefit rate of 25.3{\%}, and an overall response rate of 8.9{\%} were observed per modified International Myeloma Working Group criteria. Median progression-free survival at the RD was 10.9 months. PIM447 was well tolerated and demonstrated single-agent antitumor activity in relapsed/refractory MM patients, providing proof of principle for Pim (Proviral Insertions of Moloney Murine leukemia virus) kinase inhibition as a novel therapeutic approach in MM.",
author = "Raab, {Marc S.} and Thomas, {Sheeba K.} and Ocio, {Enrique M.} and Andreas Guenther and Goh, {Yeow Tee} and Moshe Talpaz and Nicolas Hohmann and Sylvia Zhao and Fang Xiang and Carl Simon and Vanasse, {K. Gary} and Kumar, {Shaji K}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-019-0482-0",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

AU - Raab, Marc S.

AU - Thomas, Sheeba K.

AU - Ocio, Enrique M.

AU - Guenther, Andreas

AU - Goh, Yeow Tee

AU - Talpaz, Moshe

AU - Hohmann, Nicolas

AU - Zhao, Sylvia

AU - Xiang, Fang

AU - Simon, Carl

AU - Vanasse, K. Gary

AU - Kumar, Shaji K

PY - 2019/1/1

Y1 - 2019/1/1

N2 - PIM447, a novel pan-PIM inhibitor, has shown preclinical activity in multiple myeloma (MM). In the multicenter, open-label, first-in-human study, patients with relapsed and/or refractory MM were enrolled to determine the maximum-tolerated dose (MTD) or recommended dose (RD), safety, pharmacokinetics, and preliminary anti-myeloma activity of PIM447. PIM447 was administered in escalating oral doses of 70–700 mg once daily (q.d.) for 28-day continuous cycles. Seventy-nine patients with a median of four prior therapies were enrolled. Seventy-seven patients (97.5%) had an adverse event (AE) suspected as treatment related, with treatment-related grade 3/4 AEs being mostly hematologic. Eleven dose-limiting toxicities occurred, and an MTD of 500 mg q.d. and an RD of 300 mg q.d. were established. The main reason for discontinuation was disease progression in 54 patients (68.4%). In the entire study population, a disease control rate of 72.2%, a clinical benefit rate of 25.3%, and an overall response rate of 8.9% were observed per modified International Myeloma Working Group criteria. Median progression-free survival at the RD was 10.9 months. PIM447 was well tolerated and demonstrated single-agent antitumor activity in relapsed/refractory MM patients, providing proof of principle for Pim (Proviral Insertions of Moloney Murine leukemia virus) kinase inhibition as a novel therapeutic approach in MM.

AB - PIM447, a novel pan-PIM inhibitor, has shown preclinical activity in multiple myeloma (MM). In the multicenter, open-label, first-in-human study, patients with relapsed and/or refractory MM were enrolled to determine the maximum-tolerated dose (MTD) or recommended dose (RD), safety, pharmacokinetics, and preliminary anti-myeloma activity of PIM447. PIM447 was administered in escalating oral doses of 70–700 mg once daily (q.d.) for 28-day continuous cycles. Seventy-nine patients with a median of four prior therapies were enrolled. Seventy-seven patients (97.5%) had an adverse event (AE) suspected as treatment related, with treatment-related grade 3/4 AEs being mostly hematologic. Eleven dose-limiting toxicities occurred, and an MTD of 500 mg q.d. and an RD of 300 mg q.d. were established. The main reason for discontinuation was disease progression in 54 patients (68.4%). In the entire study population, a disease control rate of 72.2%, a clinical benefit rate of 25.3%, and an overall response rate of 8.9% were observed per modified International Myeloma Working Group criteria. Median progression-free survival at the RD was 10.9 months. PIM447 was well tolerated and demonstrated single-agent antitumor activity in relapsed/refractory MM patients, providing proof of principle for Pim (Proviral Insertions of Moloney Murine leukemia virus) kinase inhibition as a novel therapeutic approach in MM.

UR - http://www.scopus.com/inward/record.url?scp=85065911295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065911295&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0482-0

DO - 10.1038/s41375-019-0482-0

M3 - Article

AN - SCOPUS:85065911295

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -